Browse Category

Health News News 23 August 2025 - 22 October 2025

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Alliance Triggers Record Rally GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singapore ts2.tech. Samsung Electronics is also participating and…
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Stock Price Surge & Recent Performance Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher (CNPV) for cytisinicline’s vaping cessation indication Investing. This rally propelled the shares to multi-month highs…
17 October 2025
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge Stocktwits. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly (up about 0.6% in pre-market trading) after…
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Korea Investing Prnewswire. This collaboration gives Samsung “a strong…
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Stock Price & Recent Performance Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading (October 14) to roughly $0.36 on the cancer data announcement Benzinga Benzinga. That rally brought the stock briefly near its 30-day resistance around $0.26 Ainvest. Before this…
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Stock Performance & Recent Price Action Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits (post-reverse-split). At the close on Oct 3, 2025, shares stood at $8.82 (market cap ~$4.8M) Stocktitan after a period of relatively low activity. That calm…
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

What is the “Stratus” COVID variant? “Stratus” is the colloquial name for XFG, a recombinant Omicron descendant (from LF.7 and LP.8.1.2). WHO added XFG to its monitoring list in late June and, based on available evidence, concluded the “additional public‑health risk … is low.” WHO’s lab summary notes spike‑protein changes (e.g., at positions 478 and 487) that can modestly increase…
28 September 2025
Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

Possible Life on Mars, ‘Black Hole Stars’ and a Global Diabetes Bombshell – Science News Roundup (Sept 15–16, 2025)

NASA Rover Finds Possible Biosignature – Closest Hint Yet of Life on Mars In a sensational development for astrobiology, NASA announced that Perseverance has collected a Mars rock sample that “could preserve evidence of ancient microbial life” Nasa. The rover drilled the sample, nicknamed “Sapphire Canyon,” from an ancient riverbed formation rich in clay – exactly the kind of environment…
16 September 2025
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children…
29 August 2025
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval Pharmexec Biopharmadive; BioPharmaDive on Dawnzera pricing and positioning Biopharmadive Biopharmadive; AbbVie Rinvoq AA trial via FiercePharma Fiercepharma; Lancet Neurology SAPPHIRE trial results Neurologylive Neurologylive; Reuters – Kite/Gilead’s Interius acquisition Reuters and Interius…

Stock Market Today

  • Hamilton Insurance Group Undervalued Despite 41.4% Gains, Intrinsic Value at $181.48
    January 23, 2026, 12:17 PM EST. Hamilton Insurance Group (ticker HG) shares closed at $27.03, showing a 41.4% gain over the past year but recent declines over the last month and year to date. Despite recent price swings, Simply Wall St's valuation analysis rates the stock 5 out of 6 for undervaluation. A detailed Excess Returns model calculates an intrinsic value at approximately $181.48 per share, suggesting HG is around 85.1% undervalued relative to its current price. This model factors in a stable earnings per share of $7.86 and a strong return on equity of 22.31%. Investors reconsidering HG amid insurance sector dynamics may find significant upside potential based on these cash flow-driven estimates.
Go toTop